Sandra Wiley
Company: MEI Pharma
Job title: Director of Translational Sciences
Seminars:
Full Audience Activity – Roundtable Discussion 4:30 pm
At your table discuss the following questions: What are the 3 most important factors to consider when selecting your modality of choice? In your mind, what are the central pros of a PROTAC degrader vs a traditional inhibitor? What feature would you prioritize as your ‘dealbreaker’ when making a final decision regarding modality?Read more
day: Day One
Voruciclib, a CDK9 inhibitor, Downregulates MYC and MCL1 and Inhibits Proliferation in Heme and Solid Tumor Models 8:30 am
Targeting transcription and phosphorylation-mediated protein degradation as an indirect mechanism to downregulate MYC and MCL1 Voruciclib synergizes with KRAS G12C and BCL2 inhibitors in preclinical solid tumor and heme malignancy models Voruciclib, in combination with venetoclax, is under clinical investigation in AMLRead more
day: Day One